Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05590624 | Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer | recruiting | N/A | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06450106 | Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy | recruiting | Phase 1 | 18 | SURGE TherapeuticsINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer |
| recruiting |
| Phase 2 |
| 58 |
| Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER |
| 1 |
| Feb 19, 2026 |
| clinicaltrials |
| NCT06111313 | The University of Miami Adapt (UAdapt) Trial | recruiting | Phase 2 | 130 | University of MiamiOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07339267 | A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer | recruiting | Phase 1 | 12 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04725903 | Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer | recruiting | N/A | 30 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06052683 | A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer. | recruiting | N/A | 208 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06303622 | Comparing MRI-Ultrasound Fusion and Cognitive-guided Biopsy for the Detection of csPCa: the PROFUSION Trial | recruiting | N/A | 1,250 | Chinese University of Hong KongOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06990542 | Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer(RadTARGET) | recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07115914 | PSMA PET for Surveillance After Focal Therapy | recruiting | N/A | 62 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407959 | Screening and Staging of Benign vs Malignant Pelvic Abnormalities | recruiting | — | 60 | Mayo ClinicOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03861676 | Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT | recruiting | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06593665 | Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.(RPLND) | recruiting | Phase 3 | 142 | Indiana UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05351424 | AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc(ADELANTE) | recruiting | N/A | 194 | Columbia UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06335914 | Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407608 | ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0(ABRUPT 2) | recruiting | — | 58 | University of Milano BicoccaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)(BAT-RAD) | recruiting | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 6, 2026 | clinicaltrials |
| NCT07391982 | Dose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions(DESTINATION 2) | recruiting | N/A | 54 | The Netherlands Cancer InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06591819 | Hypofractionated WPPT With HDR Boost | recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06631521 | Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer | recruiting | Phase 1 | 30 | AdventHealthOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07001241 | Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors | recruiting | Phase 2 | 134 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07276438 | Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial | recruiting | N/A | 186 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07325721 | Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer | recruiting | Phase 2 | 46 | Medical University of South CarolinaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389512 | Pharmaceutical Management in Targeted Radioligand Therapy(PharmTRT) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | recruiting | Phase 1 | 174 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Feb 4, 2026 | clinicaltrials |
| NCT05810467 | The Active Surveillance Study(AS) | recruiting | — | 200 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06408298 | HCQ in Resectable Localized Prostate Cancer | recruiting | Early Phase 1 | 20 | Lionel.D.Lewis, MDOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06563388 | Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial(ID-COMET) | recruiting | Phase 3 | 800 | Roswell Park Cancer InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06636526 | The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). | recruiting | — | 1,000 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07209176 | Physician- and Patient-based Barriers to NGS Testing | recruiting | N/A | 256 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06200974 | Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer(BrachyTRACKS) | recruiting | — | 100 | British Columbia Cancer AgencyOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06705803 | Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE) | recruiting | — | 3,000 | University of ChicagoOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06941363 | Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence(SUPERB) | recruiting | — | 50 | University of Milano BicoccaOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07344363 | Prostate Cancer REsearch Using Cross-validation of Innovative Sampling, Integrating LC-MS/MS for Optimized Therapeutic Drug moNitoring(PRECISION) | recruiting | — | 100 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06700057 | Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.(DOSIPROSTATE) | recruiting | — | 50 | Institut BergoniéOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06719206 | Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study(RedSedCan) | recruiting | N/A | 172 | Mälardalen UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07243834 | Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise(ADHERE) | recruiting | N/A | 160 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03322891 | Improving Health Literacy in African-American Prostate Cancer Patients | recruiting | N/A | 210 | Emory UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05806515 | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05864196 | Two Fraction Prostate SBRT With DIL SIB | recruiting | Phase 1 | 80 | NYU Langone HealthOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06099093 | Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | recruiting | Phase 4 | 30 | Brigham and Women's HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06842264 | The Development and Validation of MRI-AI-based Predictive Models for csPCa | recruiting | — | 3,000 | Peking University First HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04734730 | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | recruiting | Phase 2 | 70 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06371768 | Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors(AYA STEPS) | recruiting | N/A | 260 | Duke UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06397703 | ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer | recruiting | Phase 2 | 392 | NYU Langone HealthOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07210086 | Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R) | recruiting | Phase 2 | 50 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06636123 | GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy | recruiting | Phase 1 | 30 | Virginia Commonwealth UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07370597 | LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.(LUDOPATH) | recruiting | — | 110 | Jules Bordet InstituteOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04402151 | Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer(PSMA SBRT-SIB) | recruiting | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 19, 2026source: clinicaltrials